The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1311
Fesoterodine (Toviaz) for Overactive Bladder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the marketing of fesoterodine (Toviaz – Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this indication.

THE CONDITION — Overactive bladder is a chronic condition associated with urgency, frequency, nocturia and incontinence. It is the most common cause of incontinence in the elderly. Antimuscarinic drugs are the usual treatment for symptoms, but they cause dry mouth and constipation, and can cause confusion in elderly patients.

SUBTYPE SELECTIVITY — Some antimuscarinics are claimed to have greater affinity for muscarinic receptor subtypes involved in bladder contraction than for others. Fesoterodine, however, is not selective for subtypes of muscarinic receptors.1

PHARMACOKINETICS — Fesoterodine is a prodrug. It is well absorbed from ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fesoterodine (Toviaz) for Overactive Bladder
Article code: 1311b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian